<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/90659">
      <dc:title>Antimicrobial development in the era of emerging resistance</dc:title>
      <dc:creator>Sorlozano Puerto, Antonio</dc:creator>
      <dc:creator>Carrasco, Cristina</dc:creator>
      <dc:creator>Cabeza, José</dc:creator>
      <dc:creator>Villegas Martínez, Enrique</dc:creator>
      <dc:creator>Gutiérrez Fernández, José</dc:creator>
      <dc:subject>Faropenem</dc:subject>
      <dc:subject>Dalbavancin</dc:subject>
      <dc:subject>Telavancin</dc:subject>
      <dc:subject>Oritavancin</dc:subject>
      <dc:subject>Ceftobiprole</dc:subject>
      <dc:subject>Iclaprim</dc:subject>
      <dc:description>Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.</dc:description>
      <dc:date>2024-04-11T11:56:19Z</dc:date>
      <dc:date>2024-04-11T11:56:19Z</dc:date>
      <dc:date>2009-07</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Sorlozano A, Carrasco C, Cabeza J, Villegas E, Gutierrez J. Antimicrobial development in the era of emerging resistance. Mini Rev Med Chem. 2009 Jul;9(8):938-55. DOI:10.2174/138955709788681564</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/90659</dc:identifier>
      <dc:identifier>10.2174/138955709788681564</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 Internacional</dc:rights>
      <dc:publisher>Bentham Science Publishers</dc:publisher>
   </ow:Publication>
</rdf:RDF>